1. Home
  2. GRABW vs HUMAW Comparison

GRABW vs HUMAW Comparison

Compare GRABW & HUMAW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Grab Holdings Limited Warrant

GRABW

Grab Holdings Limited Warrant

HOLD

Current Price

$0.34

Market Cap

0.0

ML Signal

HOLD

Logo Humacyte Inc. Warrant

HUMAW

Humacyte Inc. Warrant

HOLD

Current Price

$0.15

Market Cap

0.0

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GRABW
HUMAW
Founded
2012
2004
Country
Singapore
United States
Employees
11267
220
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
N/A
N/A
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
GRABW
HUMAW
Price
$0.34
$0.15
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
54.7K
14.2K
Earning Date
02-21-2025
03-21-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$2,686,000,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
21.65
N/A
52 Week Low
$0.15
$1.18
52 Week High
$0.59
$1.34

Technical Indicators

Market Signals
Indicator
GRABW
HUMAW
Relative Strength Index (RSI) 42.87 44.95
Support Level $0.34 $0.11
Resistance Level $0.37 $0.15
Average True Range (ATR) 0.02 0.03
MACD 0.00 0.00
Stochastic Oscillator 27.09 91.78

Price Performance

Historical Comparison
GRABW
HUMAW

About GRABW Grab Holdings Limited Warrant

Founded in 2012, Grab provides ride-sharing services, food and grocery delivery, and financial services (payments, consumer loans, and enterprise offerings) in eight Southeast-Asian countries through its mobile platform. The company partners with merchants and riders, connecting them with consumers while charging commission to both sides. Grab has a leading market share in and derives 89% of its revenue from its core businesses, ride-sharing and food delivery. Singapore, Indonesia, and Malaysia contributed more than 70% of revenue in 2024. Grab's main competitors in Southeast Asia are Line Man and Goto. Its financial services business is still in its nascent stage and provides minimal revenue currently. The company now also generates advertising revenue.

About HUMAW Humacyte Inc. Warrant

Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.

Share on Social Networks: